Τίτλος:
How I treat rituximab refractory patients with WM
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Συγγραφείς:
Gavriatopoulou, M.
Ntanasis-Stathopoulos, I.
Kastritis, E.
Dimopoulos, M.A.
Περιοδικό:
OncoTargets and therapy
Εκδότης:
Impact Journals, LLC
Λέξεις-κλειδιά:
acalabrutinib; beta 2 microglobulin; Bruton tyrosine kinase; chemokine receptor CXCR4; ibrutinib; immunoglobulin enhancer binding protein; immunoglobulin M; interleukin 1 receptor associated kinase 1; interleukin 1 receptor associated kinase 4; myeloid differentiation factor 88; rituximab; zanubrutinib, aging; anemia; apoptosis; cancer immunotherapy; cancer prognosis; correlational study; CXCR4 gene; disease course; drug efficacy; drug protein binding; drug resistance; drug safety; drug screening; drug withdrawal; Editorial; enzyme activation; gold standard; health care cost; health care quality; high risk patient; human; immunoglobulin blood level; intensive care; International Prognostic Scoring System; lymphocytic infiltration; monotherapy; multicenter study (topic); MYD88 gene; MYD88L265 gene; oncogene; overall survival; phase 1 clinical trial (topic); phase 2 clinical trial (topic); progression free survival; protein secretion; randomized controlled trial (topic); somatic mutation; toxicity; treatment duration; treatment response; treatment withdrawal; tumor volume; Waldenstroem macroglobulinemia
DOI:
10.18632/oncotarget.26411
